Mercy
Iowa City Urology has partnered with
UroLift to host a virtual Men’s Health Seminar. Mercy Iowa City Urologist Luke
Brunkhorst, DO, will lead an open discussion about potential treatment for
treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH).
The
seminar, called “The Enlarged Prostate – Symptoms, Diagnosis and Treatment,”
will take place virtually via Zoom on Wednesday, April 21 at 5:30 p.m. Those who are interested can sign up using this
Zoom registration link.
Registration is confidential to protect prospective patients’ information.
“Mercy
Iowa City Urology is committed to providing patients with effective options to
address their urology needs with the best patient experience,” Dr. Brunkhorst
said. “The UroLift System has a strong safety profile and provides men
suffering from an enlarged prostate a beneficial first-line treatment
alternative to drug therapy or more invasive surgery. Importantly, the UroLift
System provides rapid relief from BPH symptoms and improves the overall quality
of life for our patients.”
Dr.
Brunkhorst is certified by the American Osteopathic Board of Surgery – Urology
and has special interests in robotic and minimally invasive surgery and
performs UroLift procedures. The UroLift System is a minimally invasive
procedure that may help relieve symptoms to allow patients to return quickly to
normal activities.
BPH,
also known as an enlarged prostate, is a common condition marked by bothersome
urinary symptoms that can cause loss of productivity, depression, interrupted sleep
and decreased quality of life. Data estimates more than 42 million men in the
U.S. are affected by BPH.
###
About Mercy Iowa City
Mercy
Iowa City is an acute care hospital and regional referral center for southeast
Iowa. Mercy has received: the Centers for Medicare and Medicaid (CMS) 5 Star
Rating as a Top 2% of all hospitals for the 4th consecutive year,
the only hospital in Iowa to do so; the Fortune IBM/Watson Health 100 Top
Hospital ranking; the accredited Chest Pain Center with the American Heart
Association Gold Plus Achievement Award for Stroke Care; the Top 100 Community
Hospitals Award in 2018 and 2019 from Becker’s Review; the Press Ganey Guardian
of Excellence Award for Mercy’s Emergency Care Unit by achieving 95 percent for
patient experience for 13 consecutive years; and the Center of Distinction
Award from Healogics for Mercy’s Wound and Vein Center. Mercy has 234 acute
care beds, 25 private rooms for outpatient surgery, a 26-bed nursery with Level
II Neonatal Intensive Care Unit, 28 primary and specialty care clinics, a
medical staff of 250 physicians representing all major medical specialties and
most subspecialties, and 1,350 employees. It was founded by the Sisters of
Mercy in 1873 and became an affiliate of MercyOne in 2017. To learn more visit www.mercyiowacity.org.
About the UroLift® System
The FDA-cleared UroLift System
is a proven, minimally invasive technology for treating lower urinary tract
symptoms due to benign prostatic hyperplasia (BPH). The UroLift permanent
implants, delivered during a minimally invasive transurethral outpatient
procedure, relieve prostate obstruction and open the urethra directly without
cutting, heating, or removing prostate tissue. Clinical data from a pivotal
206-patient randomized controlled study showed that patients with enlarged
prostate receiving UroLift implants reported rapid and durable symptomatic and
urinary flow rate improvement without compromising sexual function.*1,2
Patients also experienced significant improvement in quality of life. Most
common adverse events reported include hematuria, dysuria, micturition urgency,
pelvic pain, and urge incontinence. Most symptoms were mild to moderate in
severity and resolved within two to four weeks after the procedure.2 The
Prostatic Urethral Lift procedure using the UroLift System is recommended for
the treatment of BPH in both the American Urological Association and European
Association of Urology clinical guidelines. Over 175,000 men have been treated
with the UroLift System worldwide.** Learn more at www.UroLift.com.
* No instances of new,
sustained erectile or ejaculatory dysfunction in the LIFT pivotal study
** Management estimate based
on product sales and average units per procedure.